On Aug. 26, 2016, the U.S. Centers for Disease Control and Prevention (CDC) published 2016-17 influenza vaccination recommendations.

Routine annual influenza vaccination were recommended for all persons aged ≥6 months who do not have contraindications. For the 2016–17 influenza season, inactivated influenza vaccines (IIVs) were available in both trivalent (IIV3) and quadrivalent (IIV4) formulations.

Recombinant influenza vaccine (RIV) were available in a trivalent formulation (RIV3). In light of concerns regarding low effectiveness against influenza A(H1N1)pdm09 in the United States during the 2013–14 and 2015–16 seasons, for the 2016–17 season, ACIP makes the interim recommendation that live attenuated influenza vaccine (LAIV4) should not be used.

Vaccine virus strains included in the 2016–17 U.S. trivalent influenza vaccines will be an A/California/7/2009 (H1N1)–like virus, an A/Hong Kong/4801/2014 (H3N2)–like virus, and a B/Brisbane/60/2008–like virus (Victoria lineage). Quadrivalent vaccines included an additional influenza B virus strain, a B/Phuket/3073/2013–like virus (Yamagata lineage).